Continuous subcutaneous insulin infusion: A comprehensive review of insulin pump therapy

Archives of Internal Medicine

Volumn 161, Issue 19, 2001, Pages 2293-2300

  Lenhard, M J ^a   Reeves, G D ^a  

^a CHRISTIANA CARE HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INSULIN;

CONTINUOUS INFUSION; DIABETES CONTROL; DRUG INDICATION; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN INFUSION; INSULIN PUMP; JUVENILE DIABETES MELLITUS; MATERNAL CARE; PATIENT SELECTION; PREGNANCY; PRIORITY JOURNAL; REVIEW;

EID: 0035935061     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.161.19.2293     Document Type: Review

References (135)

1. Diabetes Control and Complications Trial (DCCT): The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin dependent diabetes mellitus
2. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)
3. Implementation of treatment protocols in the Diabetes Control and Complications Trial
4. Up and pumping: Chart your way to better control
5. Small, convenient and flexible, insulin pumps catch on
6. Novel forms of insulin delivery
7. Intensive management of insulin-dependent diabetes mellitus
8. Continuous subcutaneous insulin infusion: An approach to achieving normoglycaemia
9. Normalization of plasma glucose in juvenile diabetics by subcutaneous administration of insulin with a portable infusion pump
10. Meticulous control of diabetes: Benefits, risks and precautions
11. Mortality among diabetic patients using continuous subcutaneous insulin-infusion pumps
12. Outpatient treatment of juvenile-onset diabetes with a preprogrammed portable subcutaneous insulin infusion system
13. Long-term continuous subcutaneous insulin infusion in diabetics at home
14. The pharmacokinetics of insulin after continuous subcutaneous infusion or bolus subcutaneous injection in diabetic patients
15. Use of beef ultralente for basal insulin delivery: Plasma insulin concentrations after chronic ultralente administration in patients with I DDM
16. Comparison between continuous subcutaneous insulin infusion and multiple iniections of insulin: A one-year prospective study
17. Long-term follow-up of diabetic patients using insulin infusion pumps: Considerations for future clinical application
18. Surveillance in Florida of continuous subcutaneous insulin infusion use in cohort
19. Improved insulin sensitivity in patients with type 1 diabetes mellitus after CSII
20. Collaborative studies of the effects of continuous subcutaneous insulin infusion in insulin-dependent diabetes mellitus: Conclusions
21. Blood glucose control and the evolution of diabetic retinopathy and albuminuria: A preliminary multicenter trial
22. Two-year experience with continuous subcutaneous insulin infusion in relation to retinopathy and neuropathy
23. Continuous subcutaneous insulin infusion (CSII), multiple injections (MI), and conventional insulin therapy (CT) in self-selecting insulin-dependent diabetic patients: A comparison of metabolic control, acute complications and patient preferences
24. Effect of near normoglycaemia for two years on progression of early diabetic retinopathy, nephropathy, and neuropathy: The Oslo study
25. Improved control in diabetes with continuous subcutaneous insulin infusion
26. A crossover comparison of continuous insulin infusion and conventional injection treatment of type 1 diabetes
27. Treatment options for insulin-dependent diabetes mellitus: A comparison of the artificial endocrine pancreas, continuous subcutaneous insulin infusion, and multiple daily injections
28. Long-term metabolic control with insulin pump therapy: Report of experience with 127 patients
29. Glycemic control in insulin-dependent diabetes mellitus: Comparison of outpatient intensified conventional therapy with continuous subcutaneous insulin infusion
30. Implementation of treatment protocols in the Diabetes Control and Complications Trial
31. 1 versus blood glucose
32. Pharmacokinetics of continuous subcutaneous insulin infusion
33. Pathogenesis and prevention of the dawn phenomenon in diabetic patients treated with CSII
34. Early morning glycaemia and the metabolic consequences of delaying breakfast/morning insulin: A comparison of continuous subcutaneous insulin infusion and multiple injection therapy with human isophane or human ultralente insulin at bedtime in insulin-dependent diabetics
35. Blood glucose control on Sunday in IDDM patients: Intensified conventional insulin therapy versus continuous subcutaneous insulin infusion
36. Acute complications associated with insulin pump therapy: Report of experience with 161 patients
37. Incidence and management of severe hypoglycemia in 434 adults with insulin-dependent diabetes mellitus
38. Incidence of hypoglycemic episodes in diabetic patients under continuous subcutaneous insulin infusion and intensified conventional insulin treatment: Assessment by means of semiambulatory 24-hour continuous blood glucose monitoring
39. Identification of type I diabetic patients at increased risk for hypoglycemia during intensive therapy
40. Reduction in severe hypoglycemia with long-term continuous subcutaneous insulin infusion in type 1 diabetes
41. Efficacy and indications of CSII revisited: The Hotel Dieu cohort
42. Adrenomedullary hyperactivity in type 1 diabetic patients before and during continuous subcutaneous insulin treatment
43. Substitution of night-time continuous subcutaneous insulin infusion therapy for bedtime NPH insulin in a multiple injection regimen improves counterregulatory hormonal responses and warning symptoms of hypoglycaemia in IDDM
44. Effect of 2 years of strict metabolic control on progression of incipient nephropathy in insulin-dependent diabetes
45. Effect of two years of strict metabolic control on kidney function in long-term insulin-dependent diabetics
46. Long-term glycemic control and kidney function in insulin-dependent diabetes mellitus
47. Continuous subcutaneous insulin infusion in the management of painful diabetic neuropathy
48. Autonomic and somatosensory nerve function after 2 years of continuous subcutaneous insulin infusion in type 1 diabetes
49. Effects of continuous subcutaneous insulin infusion and intensified conventional therapy on peripheral and autonomic nerve function
50. Continuous insulin infusion therapy and retinopathy in patients with type I diabetes
51. 36 Months continuous subcutaneous insulin infusion (CSII) in insulin dependent diabetes (IDDM) - Influence on early stages of retinopathy, nephropathy and neuropathy: Psychological analysis
52. Reversal of abnormalities in ocular fluorophotometry in insulin-dependent diabetes after five to nine months of improved metabolic control
53. Beneficial effect of glycaemic improvement in non-ischaemic forms of diabetic retinopathy: A 3-year follow-up
54. Enteral hyperalimentation with continuous subcutaneous insulin infusion improved severe diarrhea in poorly controlled diabetic patient
55. Improvement of high-density lipoprotein-cholesterol levels: Ambulatory type I diabetics treated with the subcutaneous insulin pump
56. The effect of continuous subcutaneous insulin infusion on serum lipids
57. Metabolic control in newly kidney transplanted insulin-dependent diabetics: Improvement by insulin pump treatment (CSII)
58. Position statement: Education for continuous subcutaneous insulin infusion pump users
59. Patient selection for insulin pump therapy
60. Devices for insulin administration
61. Deaths among patients using continuous subcutaneous insulin infusion pumps
62. Problems and safety of continuous subcutaneous insulin infusion
63. Malfunction of continuous subcutaneous insulin infusion systems: A one-year prospective study of 127 patients
64. Diabetic ketoacidosis during long-term treatment with continuous subcutaneous insulin infusion
65. Treatment with insulin infusion pumps and ketoacidotic episodes: From physiology to troubleshooting
66. The degree/rapidity of the metabolic deterioration following interruption of a subcutaneous insulin infusion is influenced by the prevailing blood glucose level
67. Severe or life-threatening hypoglycemia in insulin pump treatment
68. Cutaneous complications of chronic continuous subcutaneous insulin infusion therapy
69. Factors related to discontinuation of subcutaneous insulin-infusion therapy
70. Acute cutaneous complications and catheter needle colonization during insulin-pump treatment
71. Cellulitus caused by Rhizomucor pusillus in a diabetic patient receiving continuous insulin infusion pump therapy
72. Carriage of Staphylococcus aureus and inflamed infusion sites with insulin-pump therapy
73. Allergic contact dermatitis from acrylates in insulin pump infusion sets
74. Nickel contact dermatitis due to the needle of an insulin pump, confirmed by microanalysis
75. Complications of insulin pump therapy: The effect of insulin preparation
76. Human insulin analogue [LYS(B28), PRO(B29)]: The ideal pump insulin?
77. Insulin lispro in CSII: Results of a double-blind crossover study
78. 1C and blood glucose stability in IDDM patients treated with lispro insulin analog in external pumps
79. Comparison of human regular and lispro insulins after interruption of continuous subcutaneous insulin infusion and in the treatment of acutely decompensated IDDM
80. Cessation of insulin infusion at night-time during CSII-therapy: Comparison of regular human insulin and insulin lispro
81. Optimal insulin delivery in adolescents with diabetes: Impact of intensive treatment or psychosocial adjustment
82. Intensified insulin therapy in the type 1 diabetic adolescent: A controlled trial
83. Comparison of continuous subcutaneous insulin infusion versus multiple daily injections in adolescents with insulin-dependent diabetes
84. Continuous subcutaneous insulin infusion in children
85. CSII: A new way to achieve strict metabolic control and lower the risk of severe hypoglycemia in adolescents
86. A primer on the use of insulin pumps in adolescents
87. Experience of subcutaneous insulin infusion in the outpatient management of diabetic teenagers
88. Continuous subcutaneous insulin infusion (CSII) in adolescents with IDDM
89. Continuous subcutaneous insulin infusion (CSII) in children and adolescents with poorly controlled type 1 diabetes
90. Continuous subcutaneous insulin infusion: A new way to lower risk of severe hypoglycemia, improve metabolic control, and enhance coping in adolescents with type 1 diabetes
91. Insulin pump therapy in young children with type 1 diabetes
92. Dispartition des accidents hypoglycemiques severes chez le tres jeune enfant diabetique traite par pompe sours-cutanee
93. Does subcutaneous insulin infusion (CSII) prolong the remission phase of insulin-dependent diabetic children?
94. Insulin pump therapy in young children with type 1 diabetes
95. Diabetic pregnancy and perinatal morbidity
96. Preconception care of diabetes: Glycemic control prevents congenital anomalies
97. Impairment of counterregulatory hormone response to hypoglycemia in pregnant women with insulin-dependent diabetes mellitus
98. Severe hypoglycemia incidence and predisposing factors in 85 pregnancies of type 1 diabetic women
99. Continuous subcutaneous insulin infusion during pregnancy
100. Preconceptional treatment with insulin infusion pumps in insulin-dependent diabetic women with particular reference to prevention of congenital malformations
101. The effect of continuous subcutaneous insulin infusion and conventional insulin regimes on 24-hour variations of blood glucose and intermediary metabolites in the third trimester of diabetic pregnancy
102. Complications and fetal outcome in diabetic pregnancy
103. Continuous subcutaneous insulin infusion versus intensive conventional insulin therapy in type I and type II diabetic pregnancy
104. Continuous subcutaneous insulin infusion (CSII) therapy during pregnancy
105. Continuous subcutaneous insulin infusion (CSII) in pregnant diabetic patients
106. Type 2 diabetes and pumps: Out on a limb?
107. Effect of 6-month gliclazide treatment on insulin release and sensitivity to endogenous insulin in NIDDM: Role of initial continuous subcutaneous insulin infusion-induced normoglycemia
108. Induction of long-term glycemic control in newly diagnosed type 2 diabetic patients by transient intensive insulin treatment
109. Improved beta-cell function after intensive insulin treatment in severe non-insulin-dependent diabetes
110. Short-term effects of continuous subcutaneous insulin infusion treatment on insulin secretion in non insulin-dependent overweight patients with poor glycaemic control despite maximal oral antidiabetic treatment
111. Prospective evaluation of HDL cholesterol changes after diet and physical conditioning programs for patients with type II diabetes mellitus
112. Hyperinsulinemia and hypofibrinolysis: Effects of short-term optimized glycemic control with continuous insulin infusion in type II diabetic patients
113. Randomized trial comparing continous subcutaneous insulin infusion and conventional insulin therapy in type II diabetic patients poorly controlled with sulfonylureas
114. Implantable insulin pump vs multiple-dose insulin for non-insulin-dependent diabetes mellitus
115. Exercise and insulin requirements
116. Hyperglycemia after intense exercise in IDDM subjects during continuous subcutaneous insulin infusion
117. Normalization of insulin sensitivity in type I diabetic subjects by physical training during insulin pump therapy
118. Exercise capacity and cardiac function in type 1 diabetic patients treated with continuous subcutaneous insulin infusion: A controlled study
119. Continuous subcutaneous insulin infusion therapy (CSII) influences cardiovascular responses to graded exercise in patients with autonomic diabetic neuropathy of the cardiovascular system (ADNCS)
120. Habitual physical activity in adult IDDM patients
121. The person and diabetes in psychosocial context
122. Psychological reactions to insulin infusion pumps
123. Personality and family profiles of chronic insulin-dependent diabetic patients using portable insulin infusion pump therapy: A preliminary investigation
124. Quality of life activities associated with adherence to insulin infusion pump therapy in the treatment of insulin-dependent diabetes mellitus
125. Lifestyle, metabolic control and social implications of pump therapy in 54 routine type 1 diabetic patients
126. Optimal insulin delivery in adolescents with diabetes: Impact of intensive treatment on psychological adjustment
127. Psychological functioning of children with insulin-dependent diabetes mellitus: A longitudinal study
128. Initiation and management of insulin pump therapy
129. Insulin pump treatment in children, adolescents, and young adults